Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

ALUMIS INC.

ALMS · Nasdaq · CIK 0001847367 · Healthcare · Biotechnology

INSIDER SIGNAL

62.6 / 100

1 buyers · 3 purchase transaction lines · $8.3M gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeStrong
RoleStrong
RecencyModerate
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+22.3 / 25
Role+20.0 / 20
Recency+5.1 / 10
Conviction+8.1 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ✓ Role scores high · most senior buyer: Director

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
AKKARAJU SRINIVASDirector
○●●▼
Pangali SanamChief Legal Officer
○▼▼
Drappa JornChief Medical Officer
○▼
Schroer John R.Chief Financial Officer
▼
Hardiman Roy C.Chief Business & Strategy Ofcr
▼
Goldstein David MChief Scientific Officer
▼
● Purchase▼ Sale○ Other

Showing the six most active owners; 5 additional owner(s) remain in Form 4 evidence.

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: AKKARAJU SRINIVAS · $8.3M
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-09-04–2026-09-08

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

62.6 / 100

Latest recorded score

↓ -0.2 ptsversus the previous recorded snapshot
  1. 63.0
  2. 63.0
  3. 62.9
  4. 62.8
  5. 62.6

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

39Purchases
9Sales
17Other Form 4 lines
33SEC filings · 365 days
BUYING3 qualifying P line(s) · 180 days
SELLING9 sale line(s) · context only
OTHER8 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-27.7%
3M
-74.5%
6M
-68.9%
12M
+61.6%

Volatility & liquidity

Volatility
122.9%
Beta
—
Avg daily value
USD 17.7M

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
-80.8%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: ROE · Fiscal year ended: 2025-12-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
10,295,705
Previous report
6,299,106
Avg daily volume
2,869,547
Days to cover
3.6

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-08AKKARAJU SRINIVASPurchase (P)Common Stock546,581USD 10.63USD 5,810,156SEC filing ↗
2026-09-04AKKARAJU SRINIVASPurchase (P)Common Stock220,070USD 11.17USD 2,458,182SEC filing ↗
2026-01-09AKKARAJU SRINIVASPurchase (P)Common Stock588,235USD 17.00USD 9,999,995SEC filing ↗
2026-01-08Tananbaum James B.Purchase (P)Common Stock411,764USD 17.00USD 6,999,988SEC filing ↗
2026-01-08Foresite Labs Affiliates 2021, LLC; Foresite Labs, LLCPurchase (P)Common Stock411,764USD 17.00USD 6,999,988SEC filing ↗
2026-01-08Foresite Capital Fund V, L.P.; Foresite Capital Fund VI LP; Foresite Capital Management V, LLC; Foresite Capital Management VI LLC; Foresite Capital Opportunity Fund V, L.P.; Foresite Capital Opportunity Management V, LLC; Foresite Labs Fund I, L.P.; Foresite Labs Management I, LLC; Labs Co-Invest V, LLCPurchase (P)Common Stock411,764USD 17.00USD 6,999,988SEC filing ↗
2025-12-05AKKARAJU SRINIVASPurchase (P)Common Stock186,377USD 9.84USD 1,833,760SEC filing ↗
2025-12-04AKKARAJU SRINIVASPurchase (P)Common Stock66,027USD 8.18USD 540,101SEC filing ↗
2025-12-03AKKARAJU SRINIVASPurchase (P)Common Stock100,000USD 7.75USD 775,000SEC filing ↗
2025-12-02AKKARAJU SRINIVASPurchase (P)Common Stock96,000USD 7.55USD 724,800SEC filing ↗
2025-12-01AKKARAJU SRINIVASPurchase (P)Common Stock86,350USD 7.46USD 644,171SEC filing ↗
2025-11-28AKKARAJU SRINIVASPurchase (P)Common Stock38,702USD 7.64USD 295,683SEC filing ↗
2025-11-26AKKARAJU SRINIVASPurchase (P)Common Stock48,537USD 7.64USD 370,823SEC filing ↗
2025-11-21Tananbaum James B.Purchase (P)Common Stock72,212USD 7.38USD 532,925SEC filing ↗
2025-11-21Foresite Labs Affiliates 2021, LLC; Foresite Labs, LLCPurchase (P)Common Stock72,212USD 7.38USD 532,925SEC filing ↗

Form 4 evidence

65 transaction lines in the latest 365-day window; 151 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-08AKKARAJU SRINIVASSale (S)Common Stock96,131USD 10.55USD 1,014,182SEC filing ↗
2026-09-08AKKARAJU SRINIVASPurchase (P)Common Stock546,581USD 10.63USD 5,810,156SEC filing ↗
2026-09-04AKKARAJU SRINIVASPurchase (P)Common Stock220,070USD 11.17USD 2,458,182SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-08AKKARAJU SRINIVASSale (S)Common Stock96,131USD 10.55USD 1,014,182SEC filing ↗
2026-09-08AKKARAJU SRINIVASPurchase (P)Common Stock546,581USD 10.63USD 5,810,156SEC filing ↗
2026-09-04AKKARAJU SRINIVASPurchase (P)Common Stock220,070USD 11.17USD 2,458,182SEC filing ↗
2026-08-03Schroer John R.Sale (S)Common Stock3,282USD 26.37USD 86,546SEC filing ↗
2026-08-03Pangali SanamSale (S)Common Stock1,364USD 26.37USD 35,969SEC filing ↗
2026-08-03Hardiman Roy C.Sale (S)Common Stock2,692USD 26.37USD 70,988SEC filing ↗
2026-08-03Goldstein David MSale (S)Common Stock2,596USD 26.37USD 68,457SEC filing ↗
2026-08-03Drappa JornSale (S)Common Stock2,447USD 26.37USD 64,527SEC filing ↗
2026-08-03Bradley Mark ChristopherSale (S)Common Stock2,572USD 26.37USD 67,824SEC filing ↗
2026-07-06Pangali SanamSale (S)Common Stock5,000USD 28.00USD 140,000SEC filing ↗
2026-07-06Pangali SanamOption exercise / conversion (M)Common Stock5,000USD 5.06USD 25,300SEC filing ↗
2026-06-30Yao ZhengbinAward / grant (A)Common Stock3,553USD 0.00USD 0SEC filing ↗
2026-06-30TETRAULT LYNN A.Award / grant (A)Common Stock3,553USD 0.00USD 0SEC filing ↗
2026-06-30Srivastava SapnaAward / grant (A)Common Stock3,553USD 0.00USD 0SEC filing ↗
2026-06-30Machado PatrickAward / grant (A)Common Stock3,553USD 0.00USD 0SEC filing ↗
2026-06-30AKKARAJU SRINIVASAward / grant (A)Common Stock3,553USD 0.00USD 0SEC filing ↗
2026-05-22Drappa JornOption exercise / conversion (M)Common Stock26,852USD 6.65USD 178,649SEC filing ↗
2026-04-01Tananbaum James B.J (J)Common Stock2,980,293USD 0.00USD 0SEC filing ↗
2026-04-01Foresite Labs Affiliates 2021, LLC; Foresite Labs, LLCJ (J)Common Stock2,980,293USD 0.00USD 0SEC filing ↗
2026-04-01Foresite Capital Fund V, L.P.; Foresite Capital Fund VI LP; Foresite Capital Management V, LLC; Foresite Capital Management VI LLC; Foresite Capital Opportunity Fund V, L.P.; Foresite Capital Opportunity Management V, LLC; Foresite Labs Fund I, L.P.; Foresite Labs Management I, LLC; Labs Co-Invest V, LLCJ (J)Common Stock2,980,293USD 0.00USD 0SEC filing ↗
2026-01-09AKKARAJU SRINIVASPurchase (P)Common Stock588,235USD 17.00USD 9,999,995SEC filing ↗
2026-01-08Tananbaum James B.Purchase (P)Common Stock411,764USD 17.00USD 6,999,988SEC filing ↗
2026-01-08Foresite Labs Affiliates 2021, LLC; Foresite Labs, LLCPurchase (P)Common Stock411,764USD 17.00USD 6,999,988SEC filing ↗
2026-01-08Foresite Capital Fund V, L.P.; Foresite Capital Fund VI LP; Foresite Capital Management V, LLC; Foresite Capital Management VI LLC; Foresite Capital Opportunity Fund V, L.P.; Foresite Capital Opportunity Management V, LLC; Foresite Labs Fund I, L.P.; Foresite Labs Management I, LLC; Labs Co-Invest V, LLCPurchase (P)Common Stock411,764USD 17.00USD 6,999,988SEC filing ↗
2025-12-05AKKARAJU SRINIVASPurchase (P)Common Stock186,377USD 9.84USD 1,833,760SEC filing ↗
2025-12-04AKKARAJU SRINIVASPurchase (P)Common Stock66,027USD 8.18USD 540,101SEC filing ↗
2025-12-03AKKARAJU SRINIVASPurchase (P)Common Stock100,000USD 7.75USD 775,000SEC filing ↗
2025-12-02AKKARAJU SRINIVASPurchase (P)Common Stock96,000USD 7.55USD 724,800SEC filing ↗
2025-12-01AKKARAJU SRINIVASPurchase (P)Common Stock86,350USD 7.46USD 644,171SEC filing ↗
2025-11-28AKKARAJU SRINIVASPurchase (P)Common Stock38,702USD 7.64USD 295,683SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerALMS
CIK0001847367
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history151 transaction lines from 2024-07-01 to 2026-09-08
58 P purchase lines · 9 S sale lines · 84 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.